Cancer Signaling and Epigenetics Program, Fox Chase Cancer Center, Philadelphia, PA, USA.
Hum Genet. 2022 Jul;141(7):1299-1308. doi: 10.1007/s00439-021-02386-w. Epub 2021 Oct 12.
Inborn errors of metabolism (IEM) comprise a large class of recessive genetic diseases involving disorders of cellular metabolism that tend to be caused by missense mutations in which a single incorrect amino acid is substituted in the polypeptide chain. Cystathionine beta-synthase (CBS) deficiency is an example of an IEM that causes large elevations of blood total homocysteine levels, resulting in phenotypes in several tissues. Current treatment strategies involve dietary restriction and vitamin therapy, but these are only partially effective and do not work in all patients. Over 85% of the described mutations in CBS-deficient patients are missense mutations in which the mutant protein fails to fold into an active conformation. The ability of CBS to achieve an active conformation is affected by a variety of intracellular protein networks including the chaperone system and the ubiquitin/proteasome system, collectively referred to as the proteostasis network. Proteostasis modulators are drugs that perturb various aspects of these networks. In this article, we will review the evidence that modulation of the intracellular protein folding environment can be used as a potential therapeutic strategy to treat CBS deficiency and discuss the pros and cons of such a strategy.
先天性代谢缺陷(IEM)包括一大类隐性遗传疾病,涉及细胞代谢紊乱,这些疾病往往是由多肽链中单个错误氨基酸取代引起的错义突变引起的。胱硫醚β-合酶(CBS)缺乏是一种导致血液总同型半胱氨酸水平大幅升高的 IEM ,导致多种组织出现表型。目前的治疗策略包括饮食限制和维生素治疗,但这些方法仅部分有效,并非对所有患者都有效。在 CBS 缺乏症患者中,超过 85%的描述性突变是错义突变,其中突变蛋白无法折叠成活性构象。CBS 形成活性构象的能力受到各种细胞内蛋白质网络的影响,包括伴侣蛋白系统和泛素/蛋白酶体系统,统称为蛋白质稳态网络。蛋白质稳态调节剂是一种能够扰乱这些网络各个方面的药物。在本文中,我们将回顾调节细胞内蛋白质折叠环境可作为治疗 CBS 缺乏症的潜在治疗策略的证据,并讨论这种策略的优缺点。